A Multipronged Approach Can Address Disparities in Cancer Care for Patients in Rural Communities
Clearity Foundation Blog
by taylorpond
10h ago
by Kyle Doherty Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas, including programs aimed at increasing clinical trial enrollment for these … Read more The post A Multipronged Approach Can Address Disparities in Cancer Care for Patients in Rural Communities appeared first on Clearity Foundation ..read more
Visit website
Discovery of new mechanism explains how ovarian cancer disables immune cells
Clearity Foundation Blog
by taylorpond
10h ago
by Weill Cornell Medical College Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The work, published Oct. 23 in Nature, … Read more The post Discovery of new mechanism explains how ovarian cancer disables immune cells appeared first on Clearity Foundation ..read more
Visit website
Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer
Clearity Foundation Blog
by taylorpond
1w ago
Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider registering to attend Clearity’s live webinar, “But This Is Different: Understanding and Getting Support for the Unique Needs of People with Low-Grade … Read more The post Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website
Communication gaps among clinicians may limit conversations about prognosis, hospice
Clearity Foundation Blog
by taylorpond
1w ago
Clearity’s Perspective: As this article highlights, it is important to know that you can bring up questions or concerns related to your prognosis with someone on your care team. Instead of waiting for the doctor to bring this topic up, … Read more The post Communication gaps among clinicians may limit conversations about prognosis, hospice appeared first on Clearity Foundation ..read more
Visit website
Returning To Work After Ovarian Cancer
Clearity Foundation Blog
by taylorpond
3w ago
Clearity Perspective: For some people diagnosed with ovarian cancer, an important part of their “new normal” is returning to work. This can present opportunities and challenges. The impacts of cancer, surgery, and side effects from treatment may make re-entering the … Read more The post Returning To Work After Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website
Conversation with an End-of-Life Doula
Clearity Foundation Blog
by taylorpond
3w ago
Danielle Peterson, Clearity’s Director of Education, talks with End-of-Life Doula, Vanessa Johnson, about planning for end-of-life, considerations for a ‘good death,’ and how she compassionately meets individuals and families at the end of life.   Danielle: Vanessa Johnston, thank you … Read more The post Conversation with an End-of-Life Doula appeared first on Clearity Foundation ..read more
Visit website
Sylvester Researchers Expand Ovarian Cancer Study to Africa
Clearity Foundation Blog
by taylorpond
1M ago
by Lauren Comander Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is … Read more The post Sylvester Researchers Expand Ovarian Cancer Study to Africa appeared first on Clearity Foundation ..read more
Visit website
TORL-1-23 Generates Responses in Heavily Pretreated CLDN6-Positive Solid Tumors
Clearity Foundation Blog
by taylorpond
1M ago
by Chris Ryan TORL-1-23, a Claudin-6 (CLDN6)–targeted antibody-drug conjugate (ADC), led to responses in patients with heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer. Additionally, the agent was well tolerated, according to data from the phase 1 TORL-123-001 … Read more The post TORL-1-23 Generates Responses in Heavily Pretreated CLDN6-Positive Solid Tumors appeared first on Clearity Foundation ..read more
Visit website
Dr Angeles Alvarez Secord on “Exciting” Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer
Clearity Foundation Blog
by taylorpond
1M ago
by Rose McNulty Mirvetuximab soravtansine showed promise for patients with heavily pretreated FRα-positive, platinum-sensitive ovarian cancer—a challenging patient population to treat—in the phase 2 PICCOLO trial. New data from the study presented at the European Society for Medical Oncology (ESMO) … Read more The post Dr Angeles Alvarez Secord on “Exciting” Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website
Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian Cancer
Clearity Foundation Blog
by taylorpond
1M ago
by Jason M. Broderick The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 … Read more The post Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website

Follow Clearity Foundation Blog on FeedSpot

Continue with Google
Continue with Apple
OR